Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Outline of Final Research Achievements |
In this study, we examined the role of transient receptor potential subfamily C (TRPC) 6/3 in pulmonary artreial hypertension. In mice and rat model of pulmonary hypertension, blockade of TRPC6/3 significantly inhibited elevation of pulmonary arterial pressure and right ventricular hypertrophy. These results suggest that Blockade of TRPC6/3 could be an novel therapeutic strategy for preventing pulmonary arterial hypertension.
|